In NAFLD patients, serum levels of chemokines CCL2 was associated with inflammation and advanced hepatic fibrosis, FGF21 was associated with inflammation;In murine models of NASH, CCR2/5 inhibition reduced circulating Ly6C(hi) MoMFs, and the FGF21 agonist reduced body weight, hepatic triglycerides. Here, FGF21 is linked to metabolic dysfunction-associated steatohepatitis.